Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-11 is a patented, aqueous botanical extract derived from the Amazonian vine *Uncaria tomentosa* (cat's claw), developed and trademarked by Optigenex. It is standardized to contain a minimum of 8% Carboxy Alkyl Esters (CAEs), which are identified as the primary bioactive constituents responsible for its therapeutic effects. Unlike standard cat's claw extracts, AC-11 is produced through a proprietary hot water extraction and ultra-filtration process that ensures it is free of indole alkaloids and maintains a low molecular weight (under 10,000 Daltons). The compound is primarily recognized for its ability to enhance natural DNA repair mechanisms, particularly in response to oxidative stress and UV radiation. Additionally, it demonstrates anti-inflammatory activity by inhibiting pro-inflammatory cytokines, supports immune function, stimulates the production of type III collagen, and has been shown to increase telomere length. It is utilized in both oral nutraceuticals and topical cosmetic formulations for general wellness and anti-aging applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AC-11.